<DOC>
	<DOCNO>NCT00304993</DOCNO>
	<brief_summary>Lipid abnormality people Metabolic Syndrome ( Insulin Resistance Syndrome ) characterize elevation triglyceride LDL cholesterol ; low level HDL cholesterol ; small , dense LDL particle . Statins generally change LDL particle size , often fenofibrate add . This combination may still sufficient . Niacin common third drug add treatment regimen , niacin increase insulin resistance . This study compare niacin third drug rosiglitazone , insulin sensitizer .</brief_summary>
	<brief_title>Study Niacin Rosiglitazone Dysmetabolic Dyslipidemia</brief_title>
	<detailed_description>The Metabolic Syndrome characterize atherogenic dyslipidemia consist hypertriglyceridemia , modest elevation LDL cholesterol , low level HDL cholesterol , LDL phenotype pattern B ( small , dense LDL particle ) . Statins first line therapy , reduce LDL cholesterol level without affect LDL particle size . Fenofibrate address triglyceride , HDL cholesterol level , LDL phenotype , recommend second level therapy . The third element niacin , insulin resistant patient , question whether niacin might exacerbate underlie pathophysiology Metabolic Syndrome patient . In SNARED , niacin compare insulin sensitizer rosiglitazone study subject already statin fenofibrate . All volunteer participate SNARED exhibit LDL phenotype pattern B despite statin therapy time recruitment . Comparisons LDL phenotype baseline compare measurement make 4 month statin + fenofibrate . If LDL phenotype convert pattern A ( large LDL particle ) , study endpoint . Otherwise , study subjcts randomize receive statin+fenofibrate+niacin , statin+fenofibrate+rosiglitazone six month , time lipid phenotype determined..</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Age &gt; = 18 year Fasting triglyceride &gt; 100 mg/dL Fasting plasma glucose 110128 mg/dL Nonpattern A LDL phenotype Overt diabetes mellitus Current therapy hypoglycemic agent Secondary cause dyslipidemia ( e.g . HRT , thyroid disease ) Serum creatinine &gt; 2.5 mg/dL nephrotic syndrome AST/ALT &gt; 3X upper limit normal Known gallbladder disease History gout hyperuricemia History peptic ulcer disease Hypersensitivity intolerance study drug Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>fenofibrate</keyword>
	<keyword>niacin</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>LDL phenotype pattern B</keyword>
	<keyword>small , dense LDL</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>Metabolic Syndrome</keyword>
</DOC>